11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 13.02.2026 Expectation: 1500 pips
GBPUSD temporarily recovers following BoE rate decision
Today at 10:57 AM 10
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Period: 31.07.2026 Expectation: 1000 pips
Buying ETHUSD on major dip
Today at 09:54 AM 9
Period: 31.05.2026 Expectation: 30000 pips
Investing in silver for medium term
Today at 09:53 AM 12
Brent sell
Period: 13.02.2026 Expectation: 210 pips
Brent crude stabilizes as geopolitical premium fades away
Today at 07:29 AM 13
Period: 12.02.2026 Expectation: 25000 pips
Selling ETHUSD when it bounces up to $2,250 resistance
Yesterday at 10:34 AM 24
Lyra_Moonwell1
Lyra_Moonwell1

Listed among the best MarketCheese authors
1st in the segment "Oil and gas"
Period: 31.03.2026 Expectation: 220 pips
Buy SPX starting from $6,820
Yesterday at 10:25 AM 27
Go to forecasts